LANTERN PHARMA INC

LTRNNASDAQ

🏆 #3532 by market capEarnings Aug 13US Equity

$2.78▼ $0.03 (−1.07%)

🌙 After hours$2.77▼ 0.25%Regular close · extended-hours price shown

1h—

24h▼ 1.1%

7d▲ 0.0%

14d▲ 8.6%

30d▼ 19.9%

1y▼ 37.6%

🏦Market Cap

$35M

Small Cap

📈Revenue Growth (YoY)

—

📊Gross Margin

—

💵FCF Margin

—

⚖️P/S Ratio

—

Otter Score

Fair

Trading Snapshot

Day Range: $2.74 – $2.82
52-Week Range: $1.11 – $5.25
Volume: $3.39B
Avg Volume: $2.42B
Shares Outstanding: 12.8M
Next Earnings: Sep 8, 2026

Fundamentals Snapshot

Annual Revenue: $4M
Last Q Revenue: $963,217
P/E Ratio: —
P/S Ratio: —
EPS (TTM): $-1.45
Dividend Yield: —

Why Investors Own LTRN

✓High-growth profile — revenue up +53.8% YoY with expanding US Equity exposure.
✓Healthy economics — 63% gross margin and 19% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$4M▲ +50.2% YoY

Gross Margin (TTM)

62.6%▲ +2.2% YoY

Operating Income (TTM)

$334,573▲ +50.2% YoY

Free Cash Flow (TTM)

$782,014▲ +50.2% YoY

About LANTERN PHARMA INC

Lantern Pharma Inc. is a clinical-stage biotechnology firm dedicated to revolutionizing drug development through the strategic application of artificial intelligence, machine learning, and comprehensive genomic data analysis. Their primary drug candidate, LP-100, is currently undergoing Phase II clinical trials, targeting metastatic, castration-resistant prostate cancer. The company is also advancing LP-300 as a potential combination therapy for non-small cell lung cancer adenocarcinoma, specifically in individuals who are non-smokers or have never smoked. Furthermore, their preclinical pipeline includes LP-184, an alkylating agent engineered to inflict DNA damage upon cancer cells that either overexpress specific biomarkers or exhibit mutations within their DNA repair pathways. Beyond these, Lantern Pharma maintains an antibody-drug conjugate (ADC) program for diverse cancer treatments. Central to their operations is the RADR artificial intelligence platform, which synergizes molecular data through advanced big data analytics and machine learning capabilities. Established in 2013, the company operates from its headquarters in Dallas, Texas.

🦦